OncoMatch/Clinical Trials/NCT05608213
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
Is NCT05608213 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Lenvatinib for hepatocellular carcinoma non-resectable.
Treatment: Lenvatinib — This study is conducted to evaluate the efficacy and safety of lenvatinib plus iodine-125 seed brachytherapy (Len-I) compared with lenvatinib (Len) alone for patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE).
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Patients who received prior systemic therapy ... for HCC
Cannot have received: immunotherapy
Patients who received prior ... immunotherapy ... for HCC
Cannot have received: hepatic arterial infusion chemotherapy
Patients who received prior ... hepatic arterial infusion chemotherapy (HAIC) ... for HCC
Cannot have received: radiation therapy
Patients who received prior ... radiotherapy for HCC
Lab requirements
Blood counts
platelets <50×10^9/L [excluded]; prothrombin time prolongation ≥ 4s [excluded]
Liver function
Child-Pugh class A/B
Cardiac function
Severe organ (heart, lung, kidney) dysfunction [excluded]
Child-Pugh class A/B; Hematologic examination: platelets <50×10^9/L; Prothrombin time prolongation ≥ 4s; Severe organ (heart, lung, kidney) dysfunction
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify